Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis

Cellular and Molecular Life Sciences

Volumn 59, Issue 9, 2002, Pages 1569-1576

  Bolon, B ^a   Campagnuolo, G ^a   Feige, U ^a  

^a AMGEN INC   (United States)

Author keywords

Adjuvant arthritis; Apoptosis; Osteoclast; Osteoprotegerin; Rat; Rheumatoid arthritis

Indexed keywords

ADJUVANT; OSTEOPROTEGERIN;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE EROSION; BONE MINERAL; BONE TISSUE; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; EARLY DIAGNOSIS; EVALUATION; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; RAT;

ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; BONE DENSITY; BONE RESORPTION; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HINDLIMB; JOINTS; MALE; OSTEOCLASTS; OSTEOPROTEGERIN; RATS; RATS, INBRED LEW; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

ADA; ANIMALIA;

EID: 0036710615     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8530-7     Document Type: Article

References (39)

1. Gravallese E. M., Galson D. L., Goldring S. R. and Auron P. E. (2001) The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res. 3: 6-12
2. Haynes D. R., Crotti T. N., Loric M., Bain G. I., Atkins G. J. and Findlay D. M. (2001) Osteoprotegerin and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40: 623-630
3. Kong Y. Y., Yoshida H., Sarosi I., Tan H. L., Timms E., Capparelli C., et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397: 315-323
4. Li J., Sarosi I., Yan X.-Q., Morony S., Capparelli C., Tan H. L. et al. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566-1571
5. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C. et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12: 1260-1268
6. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Luethy R. et al. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319
7. Kong Y. Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S. et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309
8. Campagnuolo G., Bolon B. and Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum. 46: 1926-1936
9. Romas E., Sims N. A., Hards D., Lindsay M., Ryan P. F. J., Dunstan C. et al. (2001) Fc-osteoprotegerin (Fc-OPG) fusion protein reduces osteoclast numbers and prevents bone destruction in rats with collagen-induced arthritis. Arthritis Rheum. 44: S267
10. Morony S., Capparelli C., Sarosi I., Lacey D. L., Dunstan C. R. and Kostenuik P. J. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61: 4432-4436
11. Bolon B., Carter C., Daris M., Morony S., Capparelli C., Hsieh A. et al. (2001) Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol. Ther. 3: 197-205
12. Bekker P. J., Holloway D., Nakanishi A., Arrighi H. M., Leese P. T. and Dunstan C. R. (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16: 348-360
13. Bromley M. and Woolley D. E. (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27: 968-975
14. Fujikawa Y., Shingu M., Torisu T., Itonaga I. and Masumi S. (1996) Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Br. J. Rheumatol. 35: 213-217
15. Takayanagi H., Oda H., Yamamoto S., Kawaguchi H., Tanaka S., Nishikawa T. et al. (1997) A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 240: 279-286
16. Toritsuka Y., Nakamura N., Lee S. B., Hashimoto J., Yasui N., Shino K. et al. (1997) Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J. Rheumatol. 24: 1690-1696
17. Bogoch E. R. and Moran E. (1998) Abnormal bone remodelling in inflammatory arthritis. Can. J. Surg. 41: 264-271
18. Gravallese E. M., Harada Y., Wang J. T., Gorn A. H., Thornhill T. S. and Goldring S. R. (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152: 943-951
19. Kuratani T., Nagata K., Kukita T., Hotokebuchi T., Nakasima A. and Iijima T. (1998) Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol. Histopathol. 13: 751-759
20. Suzuki Y., Nishikaku F., Nakatuka M. and Koga Y. (1998) Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 25: 1154-1160
21. Romas E., Bakharevski O., Hards D. K., Kartsogiannis V., Quinn J. M., Ryan P. F. et al. (2000) Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43: 821-826
22. Josien R., Wong B. R., Li H. L., Steinman R. M. and Choi Y. (1999) TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162: 2562-2568
23. Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E. et al. (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43: 250-258
24. Shigeyama Y., Pap T., Kunzler P., Simmen B. R., Gay R. E. and Gay S. (2000) Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43: 2523-2530
25. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T. et al. (2000) Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43: 259-269
26. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S. et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotege-rin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602
27. Wong B. R., Josien R. and Choi Y. (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukocyte Biol. 65: 715-724
28. Tsurukai T., Udagawa N., Matsuzaki K., Takahashi N. and Suda T. (2000) Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J. Bone Miner. Res. 18: 177-184
29. Quinn J. M., Neale S., Fujikawa Y., McGee J. O. and Athanasou N.A. (1998) Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells. Calc. Tissue Int. 62: 527-531
30. Itonaga I., Fujikawa Y., Sabokbar A., Murray D. W. and Athanasou N. A. (2000) Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J. Pathol. 192: 97-104
31. Lean J. M., Matsuo K., Fox S. W., Fuller K., Gibson F. M., Draycott G. et al. (2000) Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. Bone 27: 29-40
32. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T. et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176
33. Yasuda H., Shima N., Nakagawa N., Mochizuki S. I., Yano K., Fujise N. et al. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337
34. Akatsu T., Murakami T., Nishikawa M., Ono K., Shinomiya N., Tsuda E. et al. (1998) Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclasts. Biochem. Biophys. Res. Commun. 250: 229-234
35. Murakami T., Yamamoto M., Ono K., Nishikawa M., Nagata N. Motoyoshi K. et al. (1998) Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem. Biophys. Res. Commun. 252: 747-752
36. Lacey D. L., Tan H. L., Lu J., Kaufman S., Van G., Qiu W. R. et al. (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157: 435-448
37. Feige U., Hu Y.-L., Gasser J., Campagnuolo G., Munyakazi L. and Bolon B. (2000) Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell. Mol. Life Sci. 57: 1457-1470
38. Feige U. (2001) Osteoprotegerin. Ann. Rheum. Dis. 60 (suppl. III): 81-84
39. Majno G. and Joris I. (1995) Apoptosis, oncosis, and necrosis: An overview of cell death. Am. J. Pathol. 146: 3-15